Induction immunochemotherapy followed by definitive radiotherapy in patients with limited-stage small cell lung cancer: a multicenter study

References

1. 1.↵
   2. Zhao H,
   3. Qi Y,
   4. Zhang L,
   5. Xing M,
   6. Yang F.

   Thoracic radiotherapy timing and prognostic factors in elderly patients with limited-stage small cell lung cancer. Precis Radiat Oncol. 2024; 8: 14–21.

   OpenUrlPubMed
2. 2.↵
   2. Cheng Y,
   3. Spigel DR,
   4. Cho BC,
   5. Laktionov KK,
   6. Fang J,
   7. Chen Y, et al.

   Durvalumab after chemoradiotherapy in limited-stage small-cell lung cancer. N Engl J Med. 2024; 391: 1313–27.

   OpenUrlCrossRefPubMed
3. 3.↵
   2. Higgins K,
   3. Hu C,
   4. Ross HJ,
   5. Jabbour SK,
   6. Kozono DE,
   7. Owonikoko TK, et al.

   Concurrent chemoradiation ± atezolizumab (atezo) in limited-stage small cell lung cancer (LS-SCLC): results of NRG oncology/alliance LU005. Int J Radiat Oncol Biol Phys. 2024; 120: S2.

   OpenUrl
4. 4.↵
   2. Ngwa W,
   3. Irabor OC,
   4. Schoenfeld JD,
   5. Hesser J,
   6. Demaria S,
   7. Formenti SC.

   Using immunotherapy to boost the abscopal effect. Nat Rev Cancer. 2018; 18: 313–22.

   OpenUrlCrossRefPubMed
5. 5.↵
   2. Bradley JD,
   3. Sugawara S,
   4. Lee KH,
   5. Ostoros G,
   6. Demirkazik A,
   7. Zemanova M, et al.

   Simultaneous durvalumab and platinum-based chemoradiotherapy in unresectable stage III non-small cell lung cancer: the phase III PACIFIC-2 study. J Clin Oncol. 2025; 43: 3610–21.

   OpenUrlPubMed
6. 6.↵
   2. Peters S,
   3. Tan DSW,
   4. Gerber DE,
   5. Urbanic J,
   6. Ramalingam SS,
   7. Yu J, et al.

   65O CheckMate 73L: Phase III study comparing nivolumab (N) + concurrent chemoradiotherapy (CCRT) followed by N ± ipilimumab (I) v CCRT followed by durvalumab (D) for previously untreated, locally advanced stage (stg) III NSCLC. Immunooncol Technol. 2024; 24: 100808.
7. 7.↵
   2. Wu L,
   3. Yan Y,
   4. Xu Y.

   Induction immunochemotherapy followed by definitive chemoradiotherapy for unresectable locally advanced non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2023; 117: e75.
8. 8.↵
   2. Zhang Z,
   3. Liu X,
   4. Chen D,
   5. Yu J.

   Radiotherapy combined with immunotherapy: the dawn of cancer treatment. Signal Transduct Target Ther. 2022; 7: 258.

   OpenUrlPubMed
9. 9.↵
   2. Liu J,
   3. Blake SJ,
   4. Yong MC,
   5. Harjunpää H,
   6. Ngiow SF,
   7. Takeda K, et al.

   Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease. Cancer Discov. 2016; 6: 1382–99.

   OpenUrlAbstract/FREE Full Text
10. 10.↵
    2. Liu D,
    3. Hu M,
    4. Yang L,
    5. Ni J,
    6. Xu Y.

    PT2.13.01 A phase II trial of induction camrelizumab plus chemotherapy followed by chemoradiotherapy and consolidation in limited-stage SCLC. J Thorac Oncol. 2025; 20: S615.

    OpenUrl
11. 11.↵
    2. Guan S,
    3. Wang Y,
    4. Liu Q,
    5. Yan M,
    6. Ren K,
    7. Wang J, et al.

    Induction chemoimmunotherapy may achieve non-inferior outcomes to consolidation immunotherapy in patients with unresectable stage III NSCLC: a real-world multicenter retrospective study. Front Immunol. 2025; 16: 1591134.